An international clinical trial has found that participants who received injections of tezepelumab, a human monoclonal antibody, once every four weeks were able to reduce or even stop taking steroid medications for severe asthma entirely with no ill effects.
This is why science matters.
This is why science matters.
November 27, 2025 at 12:43 AM
An international clinical trial has found that participants who received injections of tezepelumab, a human monoclonal antibody, once every four weeks were able to reduce or even stop taking steroid medications for severe asthma entirely with no ill effects.
This is why science matters.
This is why science matters.
YES!!!! It's taken a year and a half to get there, but next week I have my first injection of Tezepelumab, a biologic for my severe asthma!
I really hope it works.
I really hope it works.
September 8, 2026 at 2:29 PM
YES!!!! It's taken a year and a half to get there, but next week I have my first injection of Tezepelumab, a biologic for my severe asthma!
I really hope it works.
I really hope it works.
Tezepelumab, heterojen bir hasta grubunda astımı kontrol altına almış.
Sonuçlar, genellikle klinik çalışmalardan dışlanan gruplarda daha iyi sonuçlar ortaya koydu.
Sonuçlar, genellikle klinik çalışmalardan dışlanan gruplarda daha iyi sonuçlar ortaya koydu.
May 18, 2026 at 3:08 PM
Tezepelumab, heterojen bir hasta grubunda astımı kontrol altına almış.
Sonuçlar, genellikle klinik çalışmalardan dışlanan gruplarda daha iyi sonuçlar ortaya koydu.
Sonuçlar, genellikle klinik çalışmalardan dışlanan gruplarda daha iyi sonuçlar ortaya koydu.
Die Ergebnisse deuten darauf hin, dass die Behandlung mit Tezepelumab Patienten mit schwerem Asthma helfen kann, ihren OCS-Gebrauch und die damit verbundene Belastung zu reduzieren, was eine breite Anwendbarkeit über Patientenphänotypen hinweg hat.
Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial
After 52 weeks of open-label tezepelumab treatment, nearly 90% of patients with OCS-dependent
severe, uncontrolled asthma had a maintenance OCS dose of 5 mg per day or less and
more than 50% completel...
www.thelancet.com
November 28, 2025 at 8:49 PM
Die Ergebnisse deuten darauf hin, dass die Behandlung mit Tezepelumab Patienten mit schwerem Asthma helfen kann, ihren OCS-Gebrauch und die damit verbundene Belastung zu reduzieren, was eine breite Anwendbarkeit über Patientenphänotypen hinweg hat.
Tezepelumab ist eine Art Antikörper, der ein Protein blockiert, das mit Entzündungen der Atemwege in Verbindung steht. Es ist in Europa seit ein paar Jahren zugelassen für die Behandlung von Asthma, das sich nur schwer kontrollieren lässt.
Asthma: Neues Medikament könnte Behandlung schwerer Fälle verbessern
Schwere Asthmaerkrankungen werden mitunter mit Steroidtabletten behandelt. Doch die haben einige Nebenwirkungen. Eine monatliche Injektion eines bereits zugelassenen Mittels könnte das Problem lösen.
www.spiegel.de
November 28, 2025 at 8:49 PM
Tezepelumab ist eine Art Antikörper, der ein Protein blockiert, das mit Entzündungen der Atemwege in Verbindung steht. Es ist in Europa seit ein paar Jahren zugelassen für die Behandlung von Asthma, das sich nur schwer kontrollieren lässt.
November 30, 2025 at 3:39 AM
First dose of tezepelumab today!
🎃 I hope Tezspire does the trick and feels like a treat.
🫁 #asthmaticcyclist #eosinophilicasthma
🎃 I hope Tezspire does the trick and feels like a treat.
🫁 #asthmaticcyclist #eosinophilicasthma
October 31, 2025 at 3:56 PM
First dose of tezepelumab today!
🎃 I hope Tezspire does the trick and feels like a treat.
🫁 #asthmaticcyclist #eosinophilicasthma
🎃 I hope Tezspire does the trick and feels like a treat.
🫁 #asthmaticcyclist #eosinophilicasthma
Tezepelumab is an epithelial cytokine blocker used to treat severe asthma; its efficacy and safety in patients with chronic rhinosinusitis with nasal polyps have been unclear. Research findings are summarized in a new Quick Take video. nej.md/4l1a0XC
#MedSky #ImmunoSky
#MedSky #ImmunoSky
April 1, 2025 at 1:00 PM
Tezepelumab is an epithelial cytokine blocker used to treat severe asthma; its efficacy and safety in patients with chronic rhinosinusitis with nasal polyps have been unclear. Research findings are summarized in a new Quick Take video. nej.md/4l1a0XC
#MedSky #ImmunoSky
#MedSky #ImmunoSky
In patients with chronic severe rhinosinusitis and nasal polyps, tezepelumab therapy led to greater reductions in polyp size and nasal congestion and less use of surgery and glucocorticoids than placebo. Full WAYPOINT trial results and Research Summary: nej.md/41kVfWr
#MedSky #ImmunoSky
#MedSky #ImmunoSky
April 2, 2025 at 4:01 PM
In patients with chronic severe rhinosinusitis and nasal polyps, tezepelumab therapy led to greater reductions in polyp size and nasal congestion and less use of surgery and glucocorticoids than placebo. Full WAYPOINT trial results and Research Summary: nej.md/41kVfWr
#MedSky #ImmunoSky
#MedSky #ImmunoSky
Severe asthma can be controlled by a monthly injection, trial finds
Severe asthma can be controlled by a monthly injection, trial finds
Tezepelumab treatment may mean asthmatics for whom inhalers are ineffective can reduce or stop taking steroids
A monthly injection could allow people with severe asthma to stop taking daily steroid tablets, a clinical trial has found.
More than 260 million people are thought to have asthma worldwide. While most can control their asthma with inhalers to treat immediate symptoms and preventive ones to reduce inflammation, those with the most severe asthma often take daily doses of oral corticosteroids as well. Continue reading...
www.theguardian.com
November 26, 2025 at 11:02 PM
Severe asthma can be controlled by a monthly injection, trial finds
Das Medikament ist seit geraumem (EMA 2022) stark beworben. Kein Wunder, bei 1250 Euro pro Monat Kosten!
Die Zulassungsstudie wird aufgrund ungenügender Ausreizung der Standardtherapie in der Kontrolle kritisiert, ich bin jetzt so alt und kenne bisher keinen Bedarf für sowas. Die Manege ist offen 😇
Die Zulassungsstudie wird aufgrund ungenügender Ausreizung der Standardtherapie in der Kontrolle kritisiert, ich bin jetzt so alt und kenne bisher keinen Bedarf für sowas. Die Manege ist offen 😇
Asthma: Kein Zusatznutzen von Tezepelumab
Der Wirkstoff Tezepelumab soll schweres unkontrolliertes Asthma verbessern. Das Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) konnte im Rahmen einer Studienauswertung jedoch keinen Zusatznutzen feststellen.
www.lungeninformationsdienst.de
November 29, 2025 at 6:42 AM
Das Medikament ist seit geraumem (EMA 2022) stark beworben. Kein Wunder, bei 1250 Euro pro Monat Kosten!
Die Zulassungsstudie wird aufgrund ungenügender Ausreizung der Standardtherapie in der Kontrolle kritisiert, ich bin jetzt so alt und kenne bisher keinen Bedarf für sowas. Die Manege ist offen 😇
Die Zulassungsstudie wird aufgrund ungenügender Ausreizung der Standardtherapie in der Kontrolle kritisiert, ich bin jetzt so alt und kenne bisher keinen Bedarf für sowas. Die Manege ist offen 😇
Does tezepelumab reduce asthma exacerbations attributed to respiratory infections in patients with severe, uncontrolled asthma compared with placebo? Irrespective of perennial allergy status? Find out: www.annallergy.org/article/S108...
Effect of tezepelumab on asthma exacerbations co-occurring with infection-attributed acute respiratory illnesses
Tezepelumab, a human monoclonal antibody, blocks the activity of thymic stromal lymphopoietin.
In the phase 2b PATHWAY (NCT02054130) and phase 3 NAVIGATOR (NCT03347279) studies,
tezepelumab reduced ex...
www.annallergy.org
February 17, 2026 at 2:56 PM
Does tezepelumab reduce asthma exacerbations attributed to respiratory infections in patients with severe, uncontrolled asthma compared with placebo? Irrespective of perennial allergy status? Find out: www.annallergy.org/article/S108...
Ja, wenn es passt sind die wirklich sehr beeindruckend. Vorher jahrelang Steroide bis zum Anschlag und dann, wie Du beschreibst, häufig innerhalb von Stunden auf einmal Ruhe und das dann anschließend auch anhaltend. Leider passt es nicht immer, aber spätestens mit Tezepelumab erwischt mans dann doch
February 14, 2026 at 9:21 AM
Ja, wenn es passt sind die wirklich sehr beeindruckend. Vorher jahrelang Steroide bis zum Anschlag und dann, wie Du beschreibst, häufig innerhalb von Stunden auf einmal Ruhe und das dann anschließend auch anhaltend. Leider passt es nicht immer, aber spätestens mit Tezepelumab erwischt mans dann doch
Over 28 weeks, adults with severe oral corticosteroid-dependent asthma were more likely to reduce daily steroid use with tezepelumab while maintaining asthma control. Some did not fully stop. doi.org/hb542g
Tezepelumab helps severe asthma patients reduce oral steroids over 28 weeks
New results from the Phase III SUNRISE clinical trial show that tezepelumab significantly reduced the need for long-term oral corticosteroid use in adults with severe oral corticosteroid-dependent asthma while maintaining asthma control and improving key clinical outcomes.
medicalxpress.com
May 30, 2026 at 6:00 PM
Over 28 weeks, adults with severe oral corticosteroid-dependent asthma were more likely to reduce daily steroid use with tezepelumab while maintaining asthma control. Some did not fully stop. doi.org/hb542g
Tezepelumab, şiddetli astım hastalarında steroid bağımlılığını azalttı.
Biyolojik tedavi, Tezepelumab, şiddetli astımı olan hastaların oral steroid kullanımını azaltmalarına ve aynı zamanda astım kontrolünü sürdürmelerine yardımcı olur.
FAZ 3👇
Biyolojik tedavi, Tezepelumab, şiddetli astımı olan hastaların oral steroid kullanımını azaltmalarına ve aynı zamanda astım kontrolünü sürdürmelerine yardımcı olur.
FAZ 3👇
May 30, 2026 at 8:08 AM
Tezepelumab, şiddetli astım hastalarında steroid bağımlılığını azalttı.
Biyolojik tedavi, Tezepelumab, şiddetli astımı olan hastaların oral steroid kullanımını azaltmalarına ve aynı zamanda astım kontrolünü sürdürmelerine yardımcı olur.
FAZ 3👇
Biyolojik tedavi, Tezepelumab, şiddetli astımı olan hastaların oral steroid kullanımını azaltmalarına ve aynı zamanda astım kontrolünü sürdürmelerine yardımcı olur.
FAZ 3👇
WAYPOINT study: In patients with chronic severe rhinosinusitis and nasal polyps, tezepelumab therapy led to greater reductions in polyp size and nasal congestion and less use of surgery and glucocorticoids than placebo. nej.md/41kVfWr
#MedSky #AAAAI25 @aaaaiorg.bsky.social
#MedSky #AAAAI25 @aaaaiorg.bsky.social
March 1, 2025 at 10:30 PM
WAYPOINT study: In patients with chronic severe rhinosinusitis and nasal polyps, tezepelumab therapy led to greater reductions in polyp size and nasal congestion and less use of surgery and glucocorticoids than placebo. nej.md/41kVfWr
#MedSky #AAAAI25 @aaaaiorg.bsky.social
#MedSky #AAAAI25 @aaaaiorg.bsky.social
...and results of the WAYPOINT study investigating the effect of #tezepelumab
www.nejm.org/doi/full/10.... in CRSwNP ☔️🏆🚀
#medsky #immunology 🧪 #AAAAI
(3/3)
www.nejm.org/doi/full/10.... in CRSwNP ☔️🏆🚀
#medsky #immunology 🧪 #AAAAI
(3/3)
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps | NEJM
Treatment with tezepelumab has been effective for sinonasal symptoms in patients with
severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps,
but its efficacy and saf...
www.nejm.org
March 4, 2025 at 2:02 PM
...and results of the WAYPOINT study investigating the effect of #tezepelumab
www.nejm.org/doi/full/10.... in CRSwNP ☔️🏆🚀
#medsky #immunology 🧪 #AAAAI
(3/3)
www.nejm.org/doi/full/10.... in CRSwNP ☔️🏆🚀
#medsky #immunology 🧪 #AAAAI
(3/3)
Monthly injection may help severe asthma patients safely reduce or stop daily oral steroid use, suggests new study in @lancetrespirmed.bsky.social
Explore the research 👉 spkl.io/63328Ae4di
Explore the research 👉 spkl.io/63328Ae4di
November 27, 2025 at 12:33 PM
Monthly injection may help severe asthma patients safely reduce or stop daily oral steroid use, suggests new study in @lancetrespirmed.bsky.social
Explore the research 👉 spkl.io/63328Ae4di
Explore the research 👉 spkl.io/63328Ae4di
#Tezepelumab significantly reduced nasal polyp size and congestion in severe #CRSwNP across all eosinophilic subgroups (non/mild to moderate/severe) with consistent benefits and no new safety concerns—reinforcing its efficacy regardless of ECRS phenotype.
#Biologics #Immunology
🔗 ino.to/9za8ETQ
#Biologics #Immunology
🔗 ino.to/9za8ETQ
Use of tezepelumab for chronic rhinosinusitis with nasal polyps by eosinophilic endotype: WAYPOINT post-hoc analysis
The phase 3 WAYPOINT study (NCT04851964) showed that tezepelumab improved outcomes
in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) including nasal
polyp size, nasal congestion and s...
ino.to
July 28, 2026 at 4:11 AM
#Tezepelumab significantly reduced nasal polyp size and congestion in severe #CRSwNP across all eosinophilic subgroups (non/mild to moderate/severe) with consistent benefits and no new safety concerns—reinforcing its efficacy regardless of ECRS phenotype.
#Biologics #Immunology
🔗 ino.to/9za8ETQ
#Biologics #Immunology
🔗 ino.to/9za8ETQ
Tezepelumab ilacının şiddetli astım hastalarında alevlenmeleri önemli ölçüde azalttığı gösterildi. Ïlacın günlük klinik uygulamada da güvenli ve etkili olduğunu ortaya koydular.
May 18, 2026 at 3:10 PM
Tezepelumab ilacının şiddetli astım hastalarında alevlenmeleri önemli ölçüde azalttığı gösterildi. Ïlacın günlük klinik uygulamada da güvenli ve etkili olduğunu ortaya koydular.
Aylık enjeksiyon, şiddetli astımı olan hastaların günlük steroid dozunu güvenli bir şekilde azaltmalarına yardımcı olur.
Ayrıca, tezepelumab tedavisiyle astım semptomlarının, akciğer fonksiyonlarının ve genel yaşam kalitesinin önemli ölçüde iyileştiği gösterildi.
Ayrıca, tezepelumab tedavisiyle astım semptomlarının, akciğer fonksiyonlarının ve genel yaşam kalitesinin önemli ölçüde iyileştiği gösterildi.
November 28, 2025 at 11:23 AM
Aylık enjeksiyon, şiddetli astımı olan hastaların günlük steroid dozunu güvenli bir şekilde azaltmalarına yardımcı olur.
Ayrıca, tezepelumab tedavisiyle astım semptomlarının, akciğer fonksiyonlarının ve genel yaşam kalitesinin önemli ölçüde iyileştiği gösterildi.
Ayrıca, tezepelumab tedavisiyle astım semptomlarının, akciğer fonksiyonlarının ve genel yaşam kalitesinin önemli ölçüde iyileştiği gösterildi.
#Tezepelumab reverses TSLP-driven metabolic rewiring in human cDC2s, which otherwise fuels pathogenic Th2 cells and metabolically impaired Tregs,revealing that blocking this upstream alarmin directly disrupts the immunometabolic foundation of type 2 airway inflammation.
#Immunology
🔗 ino.to/GevvHV1
#Immunology
🔗 ino.to/GevvHV1
August 4, 2026 at 4:03 AM
#Tezepelumab reverses TSLP-driven metabolic rewiring in human cDC2s, which otherwise fuels pathogenic Th2 cells and metabolically impaired Tregs,revealing that blocking this upstream alarmin directly disrupts the immunometabolic foundation of type 2 airway inflammation.
#Immunology
🔗 ino.to/GevvHV1
#Immunology
🔗 ino.to/GevvHV1
" tezepelumab " Pity it so hard to get a script X100 listed, 'specialists' ONLY. Mere doctors can not proscribe it.
An international clinical trial has found that participants who received injections of tezepelumab, a human monoclonal antibody, once every four weeks were able to reduce or even stop taking steroid medications for severe asthma entirely with no ill effects.
This is why science matters.
This is why science matters.
November 30, 2025 at 11:27 AM
" tezepelumab " Pity it so hard to get a script X100 listed, 'specialists' ONLY. Mere doctors can not proscribe it.